Avalo Therapeutics (AVTX) Capital Expenditures (2016 - 2023)

Avalo Therapeutics (AVTX) has 8 years of Capital Expenditures data on file, last reported at $158000.0 in Q1 2023.

• Quarterly Capital Expenditures changed N/A year-over-year to $158000.0 in Q1 2023, while the trailing twelve-month figure through Dec 2023 was $158000.0 (up 66.32% YoY) and the FY2023 annual result came in at $158000.0, up 66.32% from the prior year.
• Capital Expenditures grew to $158000.0 in Q1 2023, from $95000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $2.0 million in Q3 2021 to a low of -$1.0 million in Q4 2021.
• A 5-year average of $131501.1 and a median of $59500.0 in 2020 frame the typical range for Capital Expenditures.
• Annual changes were most pronounced in 2020 — Capital Expenditures soared 3149900.0% — and 2021, when it sank 1687.3%.
• Tracing AVTX's Capital Expenditures over 5 years: stood at $2.0 in 2019, then soared by 3149900.0% to $63000.0 in 2020, then slumped by 1687.3% to -$1.0 million in 2021, then surged by 109.5% to $95000.0 in 2022, then jumped by 66.32% to $158000.0 in 2023.
• The last three Capital Expenditures figures came in at $158000.0 (Q1 2023), $95000.0 (Q4 2022), and -$56000.0 (Q3 2022), per Business Quant data.